OR WAIT null SECS
GlaxoSmithKline plans to invest nearly $41 million to expand its operations at its facility in Montrose, the United Kingdom.
GlaxoSmithKline (GSK) plans to invest £25 million ($40.5 million) to expand its operations at its facility in Montrose, the United Kingdom, according to the Scottish Enterprise, Scotland's economic development agency. The investment is in addition to GSK’s earlier plan, announced in 2012, for investing £100 million ($162 million) in Montrose and the company’s other Scottish manufacturing site in Irvine.
With its most recent investment, GSK plans to bring production of the ingredients for four new pharmaceutical products to Montrose, according to the Scottish Enterprise. The investment will create an additional 25 new jobs for process technicians, engineers, and chemists, bringing the total GSK workforce in Scotland to more than 750. An additional fifty contractors will be employed during the construction phase. The Montrose site produces active ingredients for a number of drugs and the Irvine site produces antibiotics.
In 2012, GSK announced an initial investment of more than £100 million across its manufacturing sites in Montrose and Irvine, Scotland. This funding was targeted for manufacturing key materials for GSK’s portfolio of respiratory medicines as well as for producing aluminium adjuvants for vaccine manufacture. At Irvine, GSK's investment was targeted to increase production capacity for antibiotics.
Source: Scottish Enterprise